PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4 PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:1 0ratingsTime:08:01More inPeople Blogs Here is the original post: PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4 - Video … Continue reading →

Public release date: 6-Nov-2012 [ | E-mail | Share ] Contact: Jill Scoggins jill.scoggins@louisville.edu 502-852-7461 University of Louisville LOS ANGELES Marked sustained improvement in all patients with zero adverse effects. For a phase I clinical trial, these results are the Holy Grail. Yet researchers from the University of Louisville and Brigham and Women's Hospital today reported just such almost-never-attained data. In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks. They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration new heart tissue replacing former dead tissue killed by heart attack. "The … Continue reading →

Public release date: 6-Nov-2012 [ | E-mail | Share ] Contact: Miranda Peto mpeto@biocardia.com 650-226-0129 BioCardia, Inc. San Carlos, CA; November 6, 2012 BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection. According to the results, both the allogeneic and autologous MSCs were safe and well-tolerated at all doses and demonstrated similarly positive effects on cardiac structure and function, patient functional capacity and quality of life. Results from the POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) study were reported in a late breaker presentation titled, "Randomized Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathy," at the American Heart Association's 2012 Scientific Sessions and have been published in an article in the November 6 edition of the Journal of the American Medical Association. The POSEIDON study was cosponsored by the NIH Specialized Center for Cell Therapy, the University of Miami, and BioCardia. Joshua Hare, M.D., … Continue reading →

ScienceDaily (Nov. 6, 2012) For a phase I clinical trial, these results are the Holy Grail. Yet researchers from the University of Louisville and Brigham and Women's Hospital reported just such almost-never-attained data. In a Late-Breaking Clinical Trial session on Nov. 6 at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks. They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration -- new heart tissue replacing former dead tissue killed by heart attack. "The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart … Continue reading →

A Waikato woman is behind "ground-breaking" research she says could lead to the cure of type 1 diabetes within a year if funding can be found. Matamata-based Noela Vallis, president of the New Zealand Spinal Cord Society, said stem-cell therapy being developed in the organisation's Dunedin laboratory had potential to cure the auto-immune disease that affects more than 20,000 New Zealanders. Diabetes leads to a buildup of glucose in the bloodstream, which, untreated, can lead to dehydration and cause diabetics to go into a coma. The trials, led by Dr Jim Faed and scientist Dr Paul Turner, focus on a gradual recovery of insulin in patients by suppressing the body's auto-immune response. To do that, scientists remove a small amount of the patient's bone marrow and use it to grow stem cells in the laboratory to activate immune-suppressing properties. The activated cells are then infused back into the patient, converting aggressive cells to passive cells. Dr Turner said a Chinese-American study, published earlier this year, proved stem cells could be used to help turn off aggressive auto-immune responses. "The results were astonishing. After 12 weeks all treated patients were making their own insulin in larger amounts." But Mrs Vallis said … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/tztpjw/autologous_stem) has announced the addition of the "Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases)" report to their offering. This research report titled Autologous Cell Therapy (2012-2017) provides details about various ACT based treatments and their application areas. Every health regulatory bodies will be expecting companies and universities to develop therapy treatments, which are safer, affordable, robust, rapid, easy to use, effective and deliverable to the end user. ACT treatments for particular application areas it is safe, experiencing robust growth, minimal steps of procedure to follow and rapid in deriving the results. As for now the treatments prices are not affordable, but by the intrusion of government bodies, it will definitely experience a immense market growth. The report gives a detailed analysis about state of the art of autologous cell therapies. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company, revenue forecasting. It includes … Continue reading →

RIO DE JANEIRO--(BUSINESS WIRE)-- CryopraxisTM/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013. The phase IIA/B clinical trial study was completed in December 2011. These trials involved the use of a proprietary autologous stem cell formulation (MonocellTM) indicated for neoangiogeneses. Safety and efficacy of this product was evaluated in patients with refractory angina, a no option disease condition, characterized by severe chest pain for which there is no efficient treatment available, says the President of both Companies, Eduardo Cruz. ReACT, MonocellTMs derived product, showed evidence of safety and efficacy in our initial clinical trials. All patients included in this trial were classified as Class IV Angina in CCSAC* (the most severe class of chest pain). In the first group of patients, whose data was published**, there was a progressive and sustained improvement in angina symptoms, with 87.5% of the patients completing the clinical trial with a CCSAC score of 0 or 1. Angina symptom relief began as early as 3 months post procedure with continuing improvement through the 18th month, suggesting that angiogenesis began early, and that it kept evolving 18 months after … Continue reading →

Washington, November 6 (ANI) Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial. The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous, related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function. Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute. "This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN. "Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures … Continue reading →

Washington, November 7 (ANI) Stem cell therapy improves heart function in patients who had previous heart attacks, according to researchers from the University of Louisville and Brigham and Women's Hospital. In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks. They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration - new heart tissue replacing former dead tissue killed by heart attack. "The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in … Continue reading →

MANILA, Philippines -- The Department of Health (DOH) has announced its plan to regulate stem cell therapy in the country. Stem cell treatment involves the use of adult stem cells to treat a range of diseases. The Health Department believes that because of the complex preparation and invasive procedure involved, there needs to be a regulatory framework to protect Filipino citizens. The regulation of laboratories and practitioners involves five key points. First is a check on the credentials of people involved in the service, as stem cell treatment is a specialized field. The supply of raw materials will also have to be monitored, making sure especially that they do not come from aborted fetuses. Laboratories will be scrutinized for their procedures, sanitation and safety. Therapeutic claims, on the other hand, are also up for strict assessment, to make sure that these are based on solid scientific evidence. Finally, the DOH also wants a report on the possible failure of treatments, to find out if there are negative outcomes to stem cell therapy. "Those who are going to other countries for stem cell treatment should also check if their destination allows stem cell tourism," clarified FDA Acting Director Dr. Kenneth Hartigan-Go. … Continue reading →